Abstract:Summary
Vascularized composite allotransplants (VCAs) seem to have several unique features of clinical and experimental importance, including uniquely definable lymphatic drainage that can be easily accessed at the level of ipsilateral regional node beds. Thus, VCA offers a unique opportunity to assess the relative contribution of peripheral and secondary lymphoid tissue to the process of rejection. We transplanted hind limb grafts from C3H donors to six different groups of C57BL/6 recipients: Spleen+Map3k14−/… Show more
“…Mounting body of evidence points toward CD8 + effector T cells as the hallmark effectors of VCA rejection targeting epidermal and follicular stem cells (and to a lesser extent the microvascular endothelium), thus driving acute cellular rejection reactions ( 16 , 23 , 24 ). Besides these key effector-target cell interactions, multiple secondary effectors, in addition to other cellular targets, are involved in VCA rejection ( 17 ).…”
Section: The Hierarchy Of Effector-target Cell Interactions: Cells An...mentioning
confidence: 99%
“…Moris et al. further proposed an activating effect of T rm on NK cells in VCA rejection ( 24 ). In NK cells, this interaction coordinates increased granzyme B secretion ( 106 ).…”
Section: Secondary Effector Cells – From Natural Killer Cells To Mast...mentioning
confidence: 99%
“…IFN-g induces T h 1 responses and increases ROS levels, leading to endothelial damage in VCA grafts (104). Moris et al further proposed an activating effect of T rm on NK cells in VCA rejection (24). In NK cells, this interaction coordinates increased granzyme B secretion (106).…”
Section: Natural Killer Cells In Vca Rejection Reactionmentioning
Vascularized composite allotransplantation (VCA) is an evolving field of reconstructive surgery that has revolutionized the treatment of patients with devastating injuries, including those with limb losses or facial disfigurement. The transplanted units are typically comprised of different tissue types, including skin, mucosa, blood and lymphatic vasculature, muscle, and bone. It is widely accepted that the antigenicity of some VCA components, such as skin, is particularly potent in eliciting a strong recipient rejection response following transplantation. The fine line between tolerance and rejection of the graft is orchestrated by different cell types, including both donor and recipient-derived lymphocytes, macrophages, and other immune and donor-derived tissue cells (e.g., endothelium). Here, we delineate the role of different cell and tissue types during VCA rejection. Rejection of VCA grafts and the necessity of life-long multidrug immunosuppression remains one of the major challenges in this field. This review sheds light on recent developments in decoding the cellular signature of graft rejection in VCA and how these may, ultimately, influence the clinical management of VCA patients by way of novel therapies that target specific cellular processes.
“…Mounting body of evidence points toward CD8 + effector T cells as the hallmark effectors of VCA rejection targeting epidermal and follicular stem cells (and to a lesser extent the microvascular endothelium), thus driving acute cellular rejection reactions ( 16 , 23 , 24 ). Besides these key effector-target cell interactions, multiple secondary effectors, in addition to other cellular targets, are involved in VCA rejection ( 17 ).…”
Section: The Hierarchy Of Effector-target Cell Interactions: Cells An...mentioning
confidence: 99%
“…Moris et al. further proposed an activating effect of T rm on NK cells in VCA rejection ( 24 ). In NK cells, this interaction coordinates increased granzyme B secretion ( 106 ).…”
Section: Secondary Effector Cells – From Natural Killer Cells To Mast...mentioning
confidence: 99%
“…IFN-g induces T h 1 responses and increases ROS levels, leading to endothelial damage in VCA grafts (104). Moris et al further proposed an activating effect of T rm on NK cells in VCA rejection (24). In NK cells, this interaction coordinates increased granzyme B secretion (106).…”
Section: Natural Killer Cells In Vca Rejection Reactionmentioning
Vascularized composite allotransplantation (VCA) is an evolving field of reconstructive surgery that has revolutionized the treatment of patients with devastating injuries, including those with limb losses or facial disfigurement. The transplanted units are typically comprised of different tissue types, including skin, mucosa, blood and lymphatic vasculature, muscle, and bone. It is widely accepted that the antigenicity of some VCA components, such as skin, is particularly potent in eliciting a strong recipient rejection response following transplantation. The fine line between tolerance and rejection of the graft is orchestrated by different cell types, including both donor and recipient-derived lymphocytes, macrophages, and other immune and donor-derived tissue cells (e.g., endothelium). Here, we delineate the role of different cell and tissue types during VCA rejection. Rejection of VCA grafts and the necessity of life-long multidrug immunosuppression remains one of the major challenges in this field. This review sheds light on recent developments in decoding the cellular signature of graft rejection in VCA and how these may, ultimately, influence the clinical management of VCA patients by way of novel therapies that target specific cellular processes.
“…Vascular composite allotransplantation is an evolving field in organ transplantation since it has emerged as a viable option to repair tissue defects resulting from traumatic or other injuries in selected patients (1). Vascularized composite allografts (VCAs) consist of anatomically distinct tissues such as skin, muscles, connective tissue, bones and neurovascular elements that are transplanted as a single unit (2)(3)(4). So far, VCAs have been used in various settings including transplantation of face, upper or lower extremity, abdominal wall and genitourinary organs (4, 5) (1).…”
Section: Introductionmentioning
confidence: 99%
“…So far, VCAs have been used in various settings including transplantation of face, upper or lower extremity, abdominal wall and genitourinary organs (4, 5) (1). As with other solid organ grafts, they are limited by immune mediated rejection and a concomitant requirement for immunosuppression (2)(3)(4). Also, candidates for VCA are frequently sensitized, making them susceptible for antibodymediated rejection (AMR).…”
Vascularized composite allotransplantation (VCA) is a field under research and has emerged as an alternative option for the repair of severe disfiguring defects that result from severe tissue loss in a selected group of patients. Lifelong immunosuppressive therapy, immunosuppression associated complications, and the effects of the host immune response in the graft are major concerns in this type of quality-of-life transplant. The initial management of extensive soft tissue injury can lead to the development of anti-HLA antibodies through injury-related factors, transfusion and cadaveric grafting. The role of antibody-mediated rejection, donor-specific antibody (DSA) formation and graft rejection in the context of VCA still remain poorly understood. The most common antigenic target of preexisting alloantibodies are MHC mismatches, though recognition of ABO incompatible antigens, minor histocompatibility complexes and endothelial cells has also been shown to contribute to rejection. Mechanistically, alloantibody-mediated tissue damage occurs primarily through complement fixation as well as through antibody-dependent cellular toxicity. If DSA exist, activation of complement and coagulation cascades can result in vascular thrombosis and infarction and thus rejection and graft loss. Both preexisting DSA but especially de-novo DSA are currently considered as main contributors to late allograft injury and graft failure. Desensitization protocols are currently being developed for VCA, mainly including removal of alloantibodies whereas treatment of established antibody-mediated rejection is achieved through high dose intravenous immunoglobulins. The long-term efficacy of such therapies in sensitized VCA recipients is currently unknown. The current evidence base for sensitizing events and outcomes in reconstructive transplantation is limited. However, current data show that VCA transplantation has been performed in the setting of HLA-sensitization.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.